{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient events observed","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"For the subset of subjects who showed a confirmed response as defined for each cohort, Duration of Response (DoR) was defined as the time (in weeks) from first documented evidence of response (the first response prior to confirmation) until time of documented disease progression or death due to any cause, whichever was first. If the subject did not have a documented date of progression or death, DoR was censored at the date of the last adequate assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG000","title":"Hairy Cell Leukemia (HCL)"}],"paramType":"MEDIAN","populationDescription":"ITT/Evaluable population - Primary and expansion cohorts combined. Only responders were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From first documented evidence of response (the first response prior to confirmation) until time of documented disease progression or death due to any cause, whichever comes first, assessed up to 92 months (cut-off date for end of study = 10-Dec-21)","title":"Duration of Response (DoR) in the Hairy Cell Leukemia (HCL) Cohort","type":"SECONDARY","unitOfMeasure":"Weeks"}